Source:http://linkedlifedata.com/resource/pubmed/id/18231909
Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
2
|
pubmed:dateCreated |
2008-1-30
|
pubmed:abstractText |
Peripheral T-cell lymphomas (PTCL) have a variable outcome. We have investigated the prognostic value of molecular staging in non-anaplastic PTCL. T-cell receptor gamma rearrangements were routinely determined in peripheral blood (n = 40) and bone marrow (n = 38) of patients with PTCL (75% unspecified) by conventional PCR at diagnosis. Tissue controls for PCR included 24 tumour biopsies. Twenty-four patients (60%) had a PCR-detectable clonal TCR gamma rearrangement in PB or BM. These TCR gamma PCR positive patients had significantly more stage IV disease (14 patients of 15 patients; P = 0.001), elevated LDH (14 of 18 patients; P = 0.04), higher IPI (16 of 21 patients; P = 0.03), more anemia (15 of 19 patients; P = 0.02) and lower platelet counts (seven of seven patients; P = 0.02). Clinical outcome of this clonal group was characterised by lower complete remission rates (37.5% vs. 62.5%), and overall response rates (58.3% vs. 87.5%; P < 0.05) as well as a significantly shorter median overall survival (12.8 vs. 30.0 months; P = 0.006). Patients with clinical stages I - III but molecular stage IV had an equally poor overall survival when compared with patients with clinical stage IV (15.8 vs. 13.9 months). In contrast, patients with CS I - III in the absence of a TCR gamma rearrangement in PB or BM had a favourable outcome with an estimated overall survival of 70% at 3 and 5 years. Molecular staging in PB and BM by TCR gamma PCR at diagnosis may serve as a useful prognostic tool in PTCL.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Feb
|
pubmed:issn |
1029-2403
|
pubmed:author |
pubmed-author:ChottAndreasA,
pubmed-author:DieckmannKarinK,
pubmed-author:EsterbauerHaraldH,
pubmed-author:FormanekMichaelM,
pubmed-author:FriedlJosefJ,
pubmed-author:GaigerAlexanderA,
pubmed-author:HauswirthAlexanderA,
pubmed-author:HronGregorG,
pubmed-author:JägerUlrichU,
pubmed-author:MannhalterChristineC,
pubmed-author:RadererMarkusM,
pubmed-author:SchützingerChristianC,
pubmed-author:SkrabsCathrinC,
pubmed-author:StiftAntonA,
pubmed-author:UffmannMartinM,
pubmed-author:WagnerOswaldO
|
pubmed:issnType |
Electronic
|
pubmed:volume |
49
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
237-46
|
pubmed:meshHeading |
pubmed-meshheading:18231909-Adult,
pubmed-meshheading:18231909-Aged,
pubmed-meshheading:18231909-Aged, 80 and over,
pubmed-meshheading:18231909-Blood Cells,
pubmed-meshheading:18231909-Bone Marrow,
pubmed-meshheading:18231909-Female,
pubmed-meshheading:18231909-Gene Rearrangement,
pubmed-meshheading:18231909-Humans,
pubmed-meshheading:18231909-Lymphoma, T-Cell, Peripheral,
pubmed-meshheading:18231909-Male,
pubmed-meshheading:18231909-Middle Aged,
pubmed-meshheading:18231909-Polymerase Chain Reaction,
pubmed-meshheading:18231909-Prognosis,
pubmed-meshheading:18231909-Receptors, Antigen, T-Cell, gamma-delta,
pubmed-meshheading:18231909-Remission Induction,
pubmed-meshheading:18231909-Survival Rate,
pubmed-meshheading:18231909-Treatment Outcome
|
pubmed:year |
2008
|
pubmed:articleTitle |
Prognostic value of T-cell receptor gamma rearrangement in peripheral blood or bone marrow of patients with peripheral T-cell lymphomas.
|
pubmed:affiliation |
Department of Internal Medicine I, Division of Hematology and Hemostaseology, Medical University of Vienna, A-1090 Vienna, Austria.
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|